Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach
Vaccines · 31.01.2025 · 13 (2) · 149
DOI: 10.3390/vaccines13020149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 31.01.2025. Verfasst von Maria da Conceição Viana Invenção und 19 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Ciência e Tecnologia de Pernambuco (FACEPE), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), CNPq/Produtividade 2020.
Abstract (Originalsprache)
Background
The rapid advancement of the pandemic caused by SARS-CoV-2 and its variants reinforced the importance of developing easy-to-edit vaccines with fast production, such as multi-epitope DNA vaccines. The present study aimed to construct a synthetic antigen multi-epitope SARS-CoV-2 to produce a DNA vaccine.
Methods
A database of previously predicted Spike and Nucleocapsid protein epitopes was created, and these epitopes were analyzed for immunogenicity, conservation, population coverage, and molecular docking.
Results
A synthetic antigen with 15 epitopes considered immunogenic, conserved even in the face of variants and that were able to anchor themselves in the appropriate HLA site, together had more than 90% worldwide coverage. A multi-epitope construct was developed with the sequences of these peptides separated from each other by linkers, cloned into the pVAX1 vector. This construct was evaluated in vivo as a DNA vaccine and elicited T CD4+ and T CD8+ cell expansion in the blood and spleen. In hematological analyses, there was an increase in lymphocytes, monocytes, and neutrophils between the two doses. Furthermore, based on histopathological analysis, the vaccines did not cause any damage to the organs analyzed.
Conclusions
The present study generated a multi-epitope synthetic vaccine antigen capable of generating antibody-mediated and cellular immune responses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil.
- Laboratory of Molecular Genetics and Biotechnology (GMBio), Department of Biology, Center for Biological and Health Sciences, Federal University of Sergipe, São Cristóvão 49100-000, Brazil.
- Laboratory of Immunological and Antitumor Analysis, Keizo Asami Immunopathology Laboratory, Department of Antibiotics, Bioscience Center, Federal University of Pernambuco, Recife 50670-901, Brazil.
- Laboratory of Cytological and Molecular Research, Department of Histology and Embriology, Federal University of Pernambuco, Recife 50670-901, Brazil.
ORCID-Profile: Maria da Conceição Viana Invenção, Larissa Silva de Macêdo, Ingrid Andrêssa de Moura, Lucas Alexandre Barbosa de Oliveira Santos, Benigno Cristofer Flores Espinoza, Samara Sousa de Pinho, Guilherme Antonio de Souza-Silva, Jacinto da Costa Silva Neto, Anna Jéssica Duarte Silva, Marcus Vinicius de Aragão Batista, Antonio Carlos de Freitas
Förderung
- Fundação de Amparo à Ciência e Tecnologia de Pernambuco (FACEPE)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
- CNPq/Produtividade 2020
- CNPq/Produtividade
- Ministério Público do Trabalho de Pernambuco (MPT-PE)
- Universidade Federal de Pernambuco—Pró-Reitoria de Pesquisa e Inovação (UFPE-PROPESQI)
Zitieren
APA
Invenção, M. D. C. V., Macêdo, L. S., Moura, I. A., Santos, L. A. B. O., Espinoza, B. C. F., Pinho, S. S., Leal, L. R. S., Santos, D. L. D., São Marcos, B. F., Elsztein, C., Sousa, G. F., Souza-Silva, G. A., Barros, B. R. D. S., Cruz, L. C. O., Maux, J. M. L., Silva Neto, J. D. C., Melo, C. M. L., Silva, A. J. D., Batista, M. V. A., & Freitas, A. C. (2025). Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach. Vaccines, 13(2), 149. https://doi.org/10.3390/vaccines13020149
Vancouver
Invenção MDCV, Macêdo LS, Moura IA, Santos LABO, Espinoza BCF, Pinho SS, et al. Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach. Vaccines. 2025;13(2):149. doi:10.3390/vaccines13020149
BibTeX
@article{Inveno2025,
author = {Invenção, Maria da Conceição Viana and Macêdo, Larissa Silva de and Moura, Ingrid Andrêssa de and Santos, Lucas Alexandre Barbosa de Oliveira and Espinoza, Benigno Cristofer Flores and Pinho, Samara Sousa de and Leal, Lígia Rosa Sales and Santos, Daffany Luana Dos and São Marcos, Bianca de França and Elsztein, Carolina and Sousa, Georon Ferreira de and Souza-Silva, Guilherme Antonio de and Barros, Bárbara Rafaela da Silva and Cruz, Leonardo Carvalho de Oliveira and Maux, Julliano Matheus de Lima and Silva Neto, Jacinto da Costa and Melo, Cristiane Moutinho Lagos de and Silva, Anna Jéssica Duarte and Batista, Marcus Vinicius de Aragão and Freitas, Antonio Carlos de},
title = {Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {2},
pages = {149},
doi = {10.3390/vaccines13020149}
}
EUVIMED